Wayne J. Riley Takes Seat on HeartFlow Board

HeartFlow Inc. has recruited an academic leader and healthcare management expert to its board.

The company has added Wayne J. Riley, M.D., to its governing body. He is president of SUNY (State University of New York), Downstate Health Sciences University, where he teaches Internal Medicine and Health Policy and Management. Riley is a U.S. Medicare Payment Advisory Commission (MedPAC) commissioner and chairs the New York Academy of Medicine’s Board of Directors.
 
“We are honored to have Dr. Riley join HeartFlow’s Board of Directors,” said William C. Weldon, board chairman, HeartFlow. “His extensive background in clinical medicine, healthcare and healthcare management will prove to be invaluable as we continue to transform the patient experience in coronary care by advancing our unique AI-enabled HeartFlow Analysis.”

Riley is President Emeritus of the 150,000-member American College of Physicians, the nation’s largest medical specialty organization, and an elected member of the National Academy of Medicine. From January 2007 to July 2013, he was the president and CEO of Meharry Medical College. Before that, Riley served as a corporate officer and member of the senior management team as vice president and vice dean for Health Affairs and Governmental Relations and associate professor of Internal Medicine at the Baylor College of Medicine in Houston, Texas.
 
Riley is an independent director of HCA Healthcare Inc., where he chairs the Patient Safety & Quality Committee and is a member of the Audit & Compliance and Nominating & Corporate Governance Committees. Additionally, he is an independent director of Compass Pathways plc, where he serves on the Compensation and Leadership Development and Nominating and Corporate Governance Committees. Riley previously served as an independent director of Vertex Pharmaceuticals and Pinnacle Financial Partners, a community bank holding company, and was a director of the Nashville Branch Bank Board of Directors of the Federal Reserve Bank of Atlanta.
 
“I am pleased to serve on the Board of Directors for HeartFlow, especially during this exciting phase of growth,” said Riley. “The HeartFlow FFRct Analysis is truly revolutionary, and I look forward to working with the Board and management team to democratize and advance access to this incredible technology for all heart disease patients.”
 
Riley earned a bachelor of arts degree from Yale University; a master of Public Health in Health Systems Management from Tulane University School of Public Health & Tropical Medicine; a medical degree from the Morehouse School of Medicine, and an MBA from Rice University’s Jesse H. Jones Graduate School of Business.
 
Starting with a standard coronary computed tomography angiogram (CTA), the HeartFlow Analysis leverages algorithms trained using deep learning (a form of AI) and highly trained analysts to create a digital, personalized 3D model of the heart. The HeartFlow Analysis then uses powerful computer algorithms to solve millions of complex equations to simulate blood flow and provides FFRct values along the coronary arteries. This information is used by physicians in evaluating the impact a blockage may be having on blood flow and determine the optimal course of treatment for each patient. A positive FFRct value (≤0.80) indicates that a coronary blockage is impeding blood flow to the heart muscle to a degree which may warrant invasive management.
 
Data demonstrating the safety, efficacy and cost-effectiveness of the HeartFlow Analysis have been published in more than 500 peer-reviewed publications, including long-term data out to five years. To date, clinicians around the world have used the HeartFlow Analysis for more than 100,000 patients to aid in the diagnosis of heart disease.
 
HeartFlow’s non-invasive HeartFlow FFRct Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. Clinicians can use this model to evaluate the impact a blockage has on blood flow and determine the best treatment for patients. The HeartFlow FFRct Analysis is commercially available in the United States, U.K., Canada, Europe and Japan.